Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Announces SNP Discovery, Reiterates Revenue Projections

NEW YORK, July 1 - DeCode Genetics announced progress in several areas of its population genetics and target discovery research today, while reiterating that it will meet its revenue and cash-burn goals for the year.


The Reykjavik, Iceland, company announced in connection with an investor meeting that it had identified a set of SNPs on chromosome 5 that increases the risk of stroke by two-fold, and another one that doubles the risk of type 2 diabetes.


The company also said it had confirmed an earlier finding of a genetic mutation that increased risk for osteoporosis in studies outside Iceland. DeCode said it would receive milestone payments from its partner, Roche, on these findings.


DeCode additionally said that small-molecule lead discovery programs for schizophrenia, atherosclerosis, and peripheral arterial occlusive disease are progressing, and that it had identified a novel kinase target for asthma.


The company said it expects to receive $45 million in revenue for the year under its current contracts, and to burn $20 million in cash. The company had $93.2 million in cash and cash equivalents at the end of 2002.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.